Determined to realize a future in which people with cancer live longer and better than ever before

Syndax

1Q21 EARNINGS PRESENTATION

Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

Syndax pipeline targets indications with significant unmet need

Menin Inhibitor Program (SNDX-5613)

- Target validated for acute leukemias
- Ph 1 data presented 2Q21
- Ph 2 initiation expected 2Q21
- Accelerated path to approval

Anti-CSF-1R Program (Axatilimab)

- Macrophage driven diseases
- Ph 1 data validates target for cGVHD, additional inflammatory / fibrotic opportunities
- Pivotal trial (AGAVE-201) ongoing

Development Opportunities

- Focused on expanding clinical pipeline through development and in-licensing

Positive initial Phase 1 results establish SNDX-5613 as the leading Menin-MLL interaction inhibitor

Well-tolerated

- No discontinuations for drug-related AEs
- Well tolerated through multiple cycles

Clear Evidence of Single Agent Activity

- Overall response rate*: 15/31 (48%)
  - 10/15 (67%) CR_{MRD-}

PK / PD, RP2D

- Dose meeting RP2D criteria identified
- Robust gene expression changes confirm MOA

** Overall response rate includes CR + CRh + CRp + CRi + MLFS observed among pts enrolled with MLLr or NPM1c Acute Leukemia*

Patient with AML (NPM1c / IDH1^{mut}) improves to full CR from CRi

30 y.o. female NPM1c



Demographics	30 y.o., female	
Diagnosis	Treatment related AML (NPM1c/IDH1^{mut}) (Stage IIB Breast Cancer July 2016)	
Prior regimens and response	Daunorubicin and Cytarabine (Vyxeos™)	Refractory
SNDX-5613 Dose	113mg q12h + Posaconazole	
Dose reduction	None	
Response	CRi MRD- at C2D1, converted to CR MRD- on C3D1, and went on to transplant	

Patient went on to transplant after cycle 3

AML, Acute myeloid leukemia; ANC, absolute neutrophil count; CR, Complete Response; CRi, Complete Response incomplete hematologic recovery; IDH1: isocitrate dehydrogenase 1 gene; NPM1: nucleophosmin 1 gene; Plt, platelets; q12h, every 12 hours.

SNDX-5613 demonstrated promising anti-leukemic activity in patients with relapsed/refractory MLLr and NPM1c leukemia

Best Response	Response Evaluable; n = 31 4/20/21	5/7/21
Overall Response Rate*	**15/31 (48%)**	**15/31 (48%)**
CR/CRh	5	7 (23%)
CRp	5	4 (13%)
CRi/MLFS	5	4 (13%)
MRD negative^ ORR	10/15 (67%)	10/15 (67%)
MLLr overall response rate	13/24 (54%)	13/24 (54%)
mNPM1 overall response rate	2/7 (29%)	2/7 (29%)

4 MRD- patients went on to receive stem cell transplant

Responses evolving over time
(changes since 4/20)

- 2 CRp improved to CR
- 1 CRi improved to CRp

** Overall Response Rate = CR + CRh + CRp + CRi + MLFS; ^ MRD status assessed locally by PCR or Flow*

Anticipate initiation of Phase 2 expansion mid-2021



Multiple commercial opportunities in acute leukemias

- **Potential fast to market regulatory path in R/R disease**
- **Subsequent approvals prioritized by medical need and commercial opportunity**
- **Collaborate and broaden utilization through combo and investigator-initiated trials**



Axatilimab: CSF-1R mAB with potential best-in-class profile



Anticipate reporting results for all 40 patients treated in the Phase 1/2 later this year

AGAVE-201 : ongoing global pivotal trial for Axatilimab in chronic GVHD

Inclusion criteria:

- 6 years and older
- Recurrent or refractory active cGVHD after at least 2 lines of systemic therapy



Primary Endpoint: Objective Response Rate (ORR) by 2014 NIH GVHD Criteria

Key Secondaries: Duration of response, improvement in modified Lee Symptom Scale

Proven ability to build the pipeline

Business development continues to be a core strength of our business

Clinical development leadership enables competitive advantage

Established relationships enhance identification and access to quality assets

From UCB

Axatilimab

From Allergan/Vitae

Menin-MLL inhibitors



Financial highlights and FY 2021 financial guidance

Ticker	SNDX (NASDAQ)
Cash and short-term investments (as of March 31, 2021)	$271.3 million
Shares Outstanding* (as of March 31, 2021)	51.6 million

2Q and 2021 Operating Expense Guidance		
	2Q 2021	FY 2021
Research and Development	$30-35 million	$90-100 million
Total Operating Expenses^	$35-40 million	$110-120 million

* *Includes 48.3 million common shares and pre-funded warrants to purchase 3.3 million common shares;*
^ *Includes ~$2.5 million non-cash stock compensation expense per quarter*

Thank you. Questions?

Syndax